Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific AR AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1 ENSG00000169083 Androgen receptor X 67544032-67730619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000001, HPA065701, CAB065764 Supported Approved Mitochondria Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable) Mixed Mixed fallopian tube: 42.6 DLGAP2 DAP-2 ENSG00000198010 Discs, large (Drosophila) homolog-associated protein 2 8 1501366-1708476 Nuclear receptors, Predicted intracellular proteins Evidence at protein level HPA030320 Uncertain Not detected Group enriched 10 cerebral cortex: 1.9;testis: 5.5 kidney,thyroid gland: 0.3 ESR1 Era, ESR, NR3A1 ENSG00000091831 Estrogen receptor 1 6 151656691-152129619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000037, HPA000449, HPA000450, CAB055099, CAB072858 Supported Approved Nucleus
Vesicles Endometrial cancer:5.47e-7 (favourable) Group enriched Group enriched 8 breast: 37.4;cervix, uterine: 127.3;endometrium: 179.7;fallopian tube: 105.5;smooth muscle: 75.9 seminal vesicle: 13.5 ESR2 Erb, NR3A2 ENSG00000140009 Estrogen receptor 2 (ER beta) 14 64084232-64338112 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB022544 Approved Nucleoplasm Not detected Tissue enhanced testis: 10.5 adrenal gland: 6.3 ESRRA ERR1, ERRa, ERRalpha, ESRL1, NR3B1 ENSG00000173153 Estrogen-related receptor alpha 11 64305572-64316743 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053785 Approved Nucleus
Nucleoli fibrillar center
Microtubules
Cytokinetic bridge Renal cancer:1.34e-7 (favourable) Expressed in all Expressed in all duodenum: 89.0 ESRRB DFNB35, ERR2, ERRb, ERRbeta, ESRL2, NR3B2 ENSG00000119715 Estrogen-related receptor beta 14 76310614-76501841 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Mixed Group enriched 6 heart muscle: 2.5;kidney: 5.2;skeletal muscle: 1.7;stomach: 1.5;testis: 1.4 breast: 0.3 ESRRG NR3B3 ENSG00000196482 Estrogen-related receptor gamma 1 216503246-217137755 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044678 Uncertain Approved Nucleus Renal cancer:1.13e-11 (favourable) Mixed Tissue enhanced parathyroid gland: 76.1 kidney: 31.1 HNF4A HNF4, MODY, MODY1, NR2A1, TCF14 ENSG00000101076 Hepatocyte nuclear factor 4, alpha 20 44355700-44434596 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004712, CAB019417 Supported Supported Nucleoplasm Tissue enhanced Group enriched 7 colon: 58.9;duodenum: 105.9;kidney: 44.3;liver: 50.9;rectum: 48.5;small intestine: 92.8;stomach: 22.1 gallbladder: 9.2 HNF4G NR2A2 ENSG00000164749 Hepatocyte nuclear factor 4, gamma 8 75407914-75566843 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005438, HPA010610 Supported Approved Nucleoplasm
Cytosol Mixed Group enriched 5 duodenum: 103.0;small intestine: 128.1 rectum: 21.4 NR0B1 AHC, AHCH, DAX1, DSS, NR0B1 ENSG00000169297 Nuclear receptor subfamily 0, group B, member 1 X 30304206-30309598 Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA070839 Supported Nucleoplasm Tissue enhanced Group enriched 7 adrenal gland: 27.9;testis: 34.9 ovary: 4.2 NR0B2 SHP ENSG00000131910 Nuclear receptor subfamily 0, group B, member 2 1 26911489-26913966 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Group enriched Tissue enhanced duodenum: 80.8;liver: 48.6 small intestine: 29.6 NR1D1 ear-1, hRev, Rev-ErbAalpha, THRA1, THRAL ENSG00000126368 Nuclear receptor subfamily 1, group D, member 1 17 40092787-40100725 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA007935 Uncertain Supported Nuclear bodies Melanoma:1.36e-4 (favourable), Colorectal cancer:1.94e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 37.5 NR1D2 BD73, EAR-1r, Hs.37288, HZF2, RVR ENSG00000174738 Nuclear receptor subfamily 1, group D, member 2 3 23945260-23980618 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053868, HPA054798 Approved Approved Nucleoplasm Renal cancer:4.47e-7 (favourable) Expressed in all Expressed in all thyroid gland: 89.9 NR1H2 LXR-b, NER, NER-I, RIP15, UNR ENSG00000131408 Nuclear receptor subfamily 1, group H, member 2 19 50329653-50382982 Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA056838, HPA070212 Uncertain Approved Nucleoplasm Colorectal cancer:9.86e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 87.8 NR1H3 LXR-a, RLD-1 ENSG00000025434 Nuclear receptor subfamily 1, group H, member 3 11 47248300-47269032 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA036443, CAB037109 Approved Renal cancer:1.40e-5 (unfavourable), Urothelial cancer:3.40e-4 (favourable), Endometrial cancer:5.05e-4 (favourable), Liver cancer:5.60e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 55.1 NR1H4 FXR, HRR-1, HRR1, RIP14 ENSG00000012504 Nuclear receptor subfamily 1, group H, member 4 12 100473708-100564413 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA047699 Approved Nucleoplasm Group enriched Tissue enhanced liver: 66.4;small intestine: 45.2 duodenum: 30.7 NR1I2 BXR, ONR1, PAR2, PXR, SXR ENSG00000144852 Nuclear receptor subfamily 1, group I, member 2 3 119780484-119818485 FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029309, HPA055121, HPA073926 Validated Nucleoplasm Group enriched Group enriched 12 colon: 9.3;duodenum: 23.2;gallbladder: 6.0;liver: 19.7;rectum: 9.4;small intestine: 26.3 stomach: 1.3 NR1I3 CAR, CAR1, MB67 ENSG00000143257 Nuclear receptor subfamily 1, group I, member 3 1 161229666-161238302 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA051365 Approved Nucleoplasm Tissue enriched Tissue enriched 9 liver: 82.0 kidney: 9.6 NR2C1 TR2, TR2-11 ENSG00000120798 Nuclear receptor subfamily 2, group C, member 1 12 95020229-95073703 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035040, HPA035041, HPA067767 Supported Supported Nucleus
Cell Junctions
Cytosol Renal cancer:1.03e-6 (unfavourable), Liver cancer:5.18e-5 (unfavourable), Urothelial cancer:5.62e-5 (favourable) Expressed in all Mixed testis: 21.8 NR2C2 hTAK1, TAK1, TR2R1, TR4 ENSG00000177463 Nuclear receptor subfamily 2, group C, member 2 3 14947584-15053600 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006313 Approved Validated Nucleoplasm Head and neck cancer:1.51e-5 (favourable) Expressed in all Expressed in all testis: 38.8 NR2E1 TLL, TLX, XTLL ENSG00000112333 Nuclear receptor subfamily 2, group E, member 1 6 108166058-108188809 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA036954, HPA055642 Approved Approved Nuclear bodies Tissue enriched Tissue enriched 46 cerebral cortex: 11.5 adrenal gland,parathyroid gland: 0.2 NR2E3 PNR, rd7, RP37 ENSG00000278570 Nuclear receptor subfamily 2, group E, member 3 15 71792638-71818259 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Mixed Not detected cervix, uterine,testis: 0.7 NR2F1 COUP-TFI, EAR-3, ERBAL3, SVP44, TCFCOUP1, TFCOUP1 ENSG00000175745 Nuclear receptor subfamily 2, group F, member 1 5 93583337-93594615 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB019281 Approved Nucleoplasm
Cytosol Urothelial cancer:1.47e-4 (unfavourable), Renal cancer:3.47e-4 (unfavourable) Expressed in all Mixed placenta: 75.3 NR2F2 ARP1, COUP-TFII, COUPTFB, NF-E3, SVP40, TFCOUP2 ENSG00000185551 Nuclear receptor subfamily 2, group F, member 2 15 96325938-96340263 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Expressed in all Tissue enhanced ovary: 360.9 endometrium: 186.6 NR2F6 EAR-2, ERBAL2 ENSG00000160113 Nuclear receptor subfamily 2, group F, member 6 19 17231883-17245940 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Endometrial cancer:4.36e-4 (unfavourable) Expressed in all Mixed duodenum: 31.8 NR3C1 GR, GRL ENSG00000113580 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 5 143277931-143435512 Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004248, CAB010435 Supported Validated Nucleoplasm
Mitochondria
Cytosol Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable) Expressed in all Expressed in all placenta: 66.4 NR3C2 MLR, MR ENSG00000151623 Nuclear receptor subfamily 3, group C, member 2 4 148078762-148444698 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009155, HPA074979 Supported Approved Nucleoplasm Renal cancer:3.10e-11 (favourable) Mixed Mixed thyroid gland: 32.1 NR4A1 GFRP1, HMR, N10, NAK-1, NGFIB, NUR77, TR3 ENSG00000123358 Nuclear receptor subfamily 4, group A, member 1 12 52022832-52059507 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059742 Supported Nucleus
Cytosol Renal cancer:6.99e-4 (favourable) Expressed in all Expressed in all adrenal gland: 753.5 NR4A2 HZF-3, NOT, NURR1, RNR1, TINUR ENSG00000153234 Nuclear receptor subfamily 4, group A, member 2 2 156324432-156342348 Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000543, CAB010481 Uncertain Supported Nuclear speckles Expressed in all Tissue enhanced adrenal gland: 175.5 ovary: 95.2 NR4A3 CHN, CSMF, MINOR, NOR1 ENSG00000119508 Nuclear receptor subfamily 4, group A, member 3 9 99821855-99866891 Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA043360 Uncertain Breast cancer:5.97e-4 (favourable) Mixed Tissue enhanced adrenal gland: 89.5 urinary bladder: 43.5 NR5A1 AD4BP, ELP, FTZ1, FTZF1, SF-1 ENSG00000136931 Nuclear receptor subfamily 5, group A, member 1 9 124481236-124507430 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level Group enriched Group enriched 6 adrenal gland: 138.2;ovary: 36.3;spleen: 154.3 testis: 19.6 NR5A2 B1F2, FTF, FTZ-F1, FTZ-F1beta, hB1F, hB1F-2, LRH-1 ENSG00000116833 Nuclear receptor subfamily 5, group A, member 2 1 200027602-200177424 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005455, HPA017067 Supported Uncertain Nuclear speckles Tissue enhanced Mixed small intestine: 19.8 NR6A1 CT150, GCNF, GCNF1, RTR ENSG00000148200 Nuclear receptor subfamily 6, group A, member 1 9 124517275-124771310 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA031461, HPA045145 Supported Nucleus Tissue enriched Tissue enriched 8 testis: 42.5 thyroid gland: 5.1 PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Supported Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 95.8;endometrium: 171.3;fallopian tube: 52.8;smooth muscle: 113.5 ovary: 19.4 PPARA hPPAR, NR1C1, PPAR ENSG00000186951 Peroxisome proliferator-activated receptor alpha 22 46150521-46243756 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058901, HPA067049 Supported Nucleus Renal cancer:4.39e-9 (favourable) Expressed in all Expressed in all kidney: 24.0 PPARD FAAR, NR1C2, NUC1, NUCII ENSG00000112033 Peroxisome proliferator-activated receptor delta 6 35342558-35428191 FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB017635 Approved Liver cancer:4.57e-4 (unfavourable) Expressed in all Expressed in all placenta: 40.1 PPARG NR1C3, PPARG1, PPARG2, PPARgamma ENSG00000132170 Peroxisome proliferator-activated receptor gamma 3 12287368-12434356 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004282, HPA051239, HPA063663 Approved Validated Nucleus
Vesicles Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 172.8 placenta: 58.6 RARA NR1B1, RAR ENSG00000131759 Retinoic acid receptor, alpha 17 40309192-40357643 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA058282 Supported Nucleus
Cytosol Endometrial cancer:2.60e-4 (favourable) Expressed in all Expressed in all gallbladder: 68.9 RARB HAP, NR1B2, RRB2 ENSG00000077092 Retinoic acid receptor, beta 3 25174332-25597932 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002617, HPA004174 Supported Validated Nucleoplasm Renal cancer:3.43e-5 (favourable) Expressed in all Mixed placenta: 20.5 RARG NR1B3, RARC ENSG00000172819 Retinoic acid receptor, gamma 12 53210567-53232980 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA053883 Supported Supported Nucleoplasm Renal cancer:3.08e-6 (unfavourable), Endometrial cancer:3.68e-6 (unfavourable) Expressed in all Tissue enhanced skin: 143.7 esophagus: 77.6 RORA NR1F1, ROR1, ROR2, ROR3, RZRA ENSG00000069667 RAR-related orphan receptor A 15 60488284-61229319 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB009861 Approved Renal cancer:5.42e-6 (favourable) Mixed Expressed in all skin: 76.4 RORB NR1F2, ROR-BETA, RZRB ENSG00000198963 RAR-related orphan receptor B 9 74497365-74693177 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA008393 Uncertain Approved Nucleus Group enriched Tissue enhanced cerebral cortex: 12.6;cervix, uterine: 14.0 prostate: 7.6 RORC NR1F3, RORG, RZRG, TOR ENSG00000143365 RAR-related orphan receptor C 1 151806071-151831872 Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA065620 Supported Nuclear bodies Renal cancer:2.94e-5 (favourable), Colorectal cancer:1.83e-4 (favourable) Mixed Mixed thyroid gland: 51.8 RXRA NR2B1 ENSG00000186350 Retinoid X receptor, alpha 9 134317098-134440585 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004565, CAB005352 Supported Supported Nucleus
Golgi apparatus Renal cancer:5.58e-4 (unfavourable), Pancreatic cancer:7.02e-4 (favourable) Expressed in all Mixed esophagus: 25.9 RXRB H-2RIIBP, NR2B2, RCoR-1 ENSG00000204231 Retinoid X receptor, beta 6 33193588-33200688 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002003, HPA063653 Approved Supported Nucleus Expressed in all Mixed epididymis: 15.5 RXRG NR2B3 ENSG00000143171 Retinoid X receptor, gamma 1 165400917-165445355 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002615 Uncertain Thyroid cancer:9.40e-5 (favourable) Group enriched Tissue enhanced skeletal muscle: 16.7 cervix, uterine: 4.6 THRA AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3 ENSG00000126351 Thyroid hormone receptor, alpha 17 40058290-40093867 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA009654, CAB023349 Uncertain Supported Cytosol Renal cancer:6.05e-8 (favourable), Lung cancer:1.84e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 239.6 THRB ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2 ENSG00000151090 Thyroid hormone receptor, beta 3 24117160-24495282 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB002008, CAB002009, HPA061035 Approved Supported Nuclear bodies Renal cancer:9.46e-8 (favourable) Mixed Mixed cerebral cortex: 36.4 VDR NR1I1, PPP1R163 ENSG00000111424 Vitamin D (1,25- dihydroxyvitamin D3) receptor 12 47841537-47943048 Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB004617, HPA047740 Validated Nucleoplasm Renal cancer:4.89e-6 (favourable) Expressed in all Tissue enhanced parathyroid gland: 172.8 small intestine: 59.2